Vidaza®

DRUG3 trials

Sponsors

Bioniche Pharma USA LLC, American Regent, Inc., Celgene

Conditions

Chronic Lymphocytic LeukemiaChronic Myeloid LeukemiaMyelodysplastic SyndromeMyelofibrosis

Phase 1

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

CompletedNCT01152346

Bioniche Pharma USA LLCMyelodysplastic Syndrome

Start: 2011-04-30End: 2013-05-31Updated: 2015-01-28

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

CompletedNCT01290302

American Regent, Inc.Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome +1

Start: 2010-11-22End: 2012-12-21Updated: 2025-06-12

Unknown Phase

Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea

CompletedNCT02137629

CelgeneMyelodysplastic Syndrome

Start: 2010-12-27End: 2016-05-19Updated: 2019-11-18